Annexon reported initial FORWARD study results for tanruprubart in Guillain-Barré syndrome, citing early signs of benefit in the first 10 patients enrolled in t

Annexon reported initial FORWARD study results for tanruprubart in Guillain-Barré syndrome, citing early signs of benefit in the first 10 patients enrolled in the U.S. and Europe. Detailed efficacy and safety data have not yet been disclosed.